Silexion Therapeutics Corp (SLXN) has a current Price-to-Book (P/B) ratio of 0.84. Compared to its 3-year average P/B ratio of 0.79, the current P/B ratio is approximately 7.14% higher. Relative to its 5-year average P/B ratio of 1.35, the current P/B ratio is about -37.39% higher. Silexion Therapeutics Corp (SLXN) has a Forward Free Cash Flow (FCF) yield of approximately -182.64%. Compared to its 3-year average FCF yield of -90.55%, the current FCF yield is approximately 101.72% lower. Relative to its 5-year average FCF yield of -52.28%, the current FCF yield is about 249.36% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SLXN competitors is 0.77, providing a benchmark for relative valuation. Silexion Therapeutics Corp Corp (SLXN.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SLXN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SLXN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SLXN currently overvalued or undervalued?

What is Silexion Therapeutics Corp (SLXN) fair value?

SLXN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Silexion Therapeutics Corp (SLXN) is between to according to relative valuation method.

How does SLXN's valuation metrics compare to the industry average?

The average P/S ratio for SLXN's competitors is 0.77, providing a benchmark for relative valuation. Silexion Therapeutics Corp Corp (SLXN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Silexion Therapeutics Corp (SLXN) as of Mar 03 2026?

As of Mar 03 2026, Silexion Therapeutics Corp (SLXN) has a P/B ratio of 0.84. This indicates that the market values SLXN at 0.84 times its book value.

What is the current FCF Yield for Silexion Therapeutics Corp (SLXN) as of Mar 03 2026?

As of Mar 03 2026, Silexion Therapeutics Corp (SLXN) has a FCF Yield of -182.64%. This means that for every dollar of Silexion Therapeutics Corp's market capitalization, the company generates -182.64 cents in free cash flow.

What is the current Forward P/E ratio for Silexion Therapeutics Corp (SLXN) as of Mar 03 2026?

As of Mar 03 2026, Silexion Therapeutics Corp (SLXN) has a Forward P/E ratio of -0.39. This means the market is willing to pay $-0.39 for every dollar of Silexion Therapeutics Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Silexion Therapeutics Corp (SLXN) as of Mar 03 2026?

As of Mar 03 2026, Silexion Therapeutics Corp (SLXN) has a Forward P/S ratio of 0.00. This means the market is valuing SLXN at $0.00 for every dollar of expected revenue over the next 12 months.

SLXN Valuation